Identifying predictors and outcomes in Myasthenia Gravis

Predictors and Prognostic Factors of Myasthenia Gravis Outcome

This study looks at the different types of Myasthenia Gravis to see what factors affect how well treatments work and to understand how often the disease doesn’t respond to treatment.

Quick facts

• Study type: Observational
• Enrollment: 30 (estimated)
• Ages: 16 Years and up
• Sex: All
• Sponsor: Assiut University (other)
• Locations: 1 site (Asyut)
• Trial ID: NCT05214612 on ClinicalTrials.gov

What this trial studies

This observational study focuses on characterizing the clinical features and frequency of different subgroups of Myasthenia Gravis (MG), an autoimmune disease affecting the neuromuscular junction. It aims to identify predictors of treatment responsiveness by assessing changes in MG scales over a three-month period and monitoring treatment-related adverse events. The study will also evaluate the prevalence of refractory MG cases to better understand disease relapse trends and optimize management strategies.

Who should consider this trial

Good fit: Ideal candidates for this study are individuals aged 16 years and older with a clinical diagnosis of Myasthenia Gravis.

Not a fit: Patients under 16 years of age or those with chronic psychiatric or neurological disorders may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved treatment strategies and outcomes for patients with Myasthenia Gravis.

How similar studies have performed: While there have been studies on Myasthenia Gravis, this particular approach focusing on predictors and prognostic factors is relatively novel.

Eligibility criteria

Inclusion Criteria:

1. Age from 16 years and older.
2. Gender: both sexes are included.
3. Clinical Diagnosis of MG with supporting evidence as:

   1. unequivocal clinical response to pyridostigmine
   2. decrement \>10% in repetitive nerve stimulations study (RNS).
4. Willingness to sample collection, imaging study and other disease-related examinations and assessments.

Exclusion Criteria:

1. Age younger than 16 years.
2. History of chronic psychiatric or neurological disorder other than MG that can produce weakness or fatigue.
3. Severe systemic illness affecting life-expectancy.

Where this trial is running

Asyut

• Assiut University — Asyut, Egypt (RECRUITING)

Study contacts

• Study coordinator: Nourelhoda AA Haridy, Lecturer

Conditions: Myasthenia Gravis, Autoimmune Diseases of the Nervous System, Neuromuscular Junction Diseases, Thymoma, Thymus Hyperplasia, Nervous System Diseases, Myasthenia Gravis, Generalized, Myasthenia Gravis, Ocular